Metastases

NICE Pathways

Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.  Find out more about NICE Pathways.

• Brain tumours and metastases

• Metastatic malignant disease of unknown primary origin

• Metastatic spinal cord compression

NICE guidelines

Review the evidence across broad health and social care topics. 

• Brain tumours (primary) and brain metastases in adults (NG99)

  New

  Yes

  Id:

  NG99

  Published date:

  July 2018

• Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

  Id:

  CG104

  Published date:

  July 2010

• Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

  Id:

  CG75

  Published date:

  November 2008

Quality standards

Set out priority areas for quality improvement in health and social care. 

• Metastatic spinal cord compression in adults (QS56)

  Id:

  QS56

  Published date:

  February 2014

• Suspected cancer (QS124)

  Id:

  QS124

  Published date:

  June 2016

Technology appraisal guidance

Review clinical and cost effectiveness of new treatments.

• Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

  Id:

  TA259

  Published date:

  June 2012

• Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

  Id:

  TA387

  Published date:

  April 2016

• Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

  Id:

  TA310

  Published date:

  April 2014

• Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

  Id:

  TA307

  Published date:

  March 2014

• Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

  Id:

  TA520

  Published date:

  May 2018

• Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

  New

  Yes

  Id:

  TA525

  Published date:

  June 2018

• Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

  Updated

  Yes

  Id:

  TA492

  Published date:

  December 2017

  Last updated:

  July 2018

• Avelumab for treating metastatic Merkel cell carcinoma (TA517)

  Id:

  TA517

  Published date:

  April 2018

• Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

  Id:

  TA178

  Published date:

  August 2009

• Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

  Id:

  TA118

  Published date:

  January 2007

• Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

  Id:

  TA214

  Published date:

  February 2011

• Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

  Id:

  TA263

  Published date:

  August 2012

• Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

  Id:

  TA212

  Published date:

  December 2010

• Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

  Id:

  TA391

  Published date:

  May 2016

• Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

  Id:

  TA439

  Published date:

  March 2017

• Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

  Id:

  TA473

  Published date:

  August 2017

• Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

  Id:

  TA242

  Published date:

  January 2012

• Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

  Id:

  TA414

  Published date:

  October 2016

• Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

  Id:

  TA321

  Published date:

  October 2014

• Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

  Id:

  TA265

  Published date:

  October 2012

• Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

  Id:

  TA101

  Published date:

  June 2006

• Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

  Id:

  TA316

  Published date:

  July 2014

• Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

  Id:

  TA377

  Published date:

  January 2016

• Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

  Id:

  TA515

  Published date:

  March 2018

• Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

  Id:

  TA423

  Published date:

  December 2016

• Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

  Id:

  TA258

  Published date:

  June 2012

• Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

  Id:

  TA449

  Published date:

  June 2017

• Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

  Id:

  TA239

  Published date:

  December 2011

• Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

  Id:

  TA503

  Published date:

  January 2018

• Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

  Id:

  TA192

  Published date:

  July 2010

• Gemcitabine for the treatment of metastatic breast cancer (TA116)

  Id:

  TA116

  Published date:

  January 2007

• Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

  Id:

  TA61

  Published date:

  May 2003

• Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

  Id:

  TA209

  Published date:

  November 2010

• Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

  Id:

  TA86

  Published date:

  October 2004

• Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

  Id:

  TA268

  Published date:

  December 2012

• Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

  Id:

  TA319

  Published date:

  July 2014

• Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

  Id:

  TA257

  Published date:

  June 2012

• Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

  New

  Yes

  Id:

  TA539

  Published date:

  August 2018

• Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

  Id:

  TA411

  Published date:

  September 2016

• Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

  Id:

  TA347

  Published date:

  July 2015

• Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

  Id:

  TA484

  Published date:

  November 2017

• Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

  Id:

  TA483

  Published date:

  November 2017

• Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

  Id:

  TA384

  Published date:

  February 2016

• Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

  New

  Yes

  Id:

  TA530

  Published date:

  July 2018

• Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

  Id:

  TA490

  Published date:

  November 2017

• Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

  Id:

  TA400

  Published date:

  July 2016

• Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

  Id:

  TA416

  Published date:

  October 2016

• Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

  Id:

  TA476

  Published date:

  September 2017

• Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

  Id:

  TA495

  Published date:

  December 2017

• Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

  Id:

  TA240

  Published date:

  December 2011

• Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)

  Id:

  TA440

  Published date:

  April 2017

• Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

  Id:

  TA366

  Published date:

  November 2015

• Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

  Id:

  TA519

  Published date:

  April 2018

• Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

  Updated

  Yes

  Id:

  TA522

  Published date:

  June 2018

  Last updated:

  July 2018

• Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

  New

  Yes

  Id:

  TA531

  Published date:

  July 2018

• Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

  Id:

  TA509

  Published date:

  March 2018

• Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

  Id:

  TA412

  Published date:

  September 2016

• Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

  Id:

  TA403

  Published date:

  August 2016

• Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)

  Id:

  TA334

  Published date:

  February 2015

• Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

  Id:

  TA488

  Published date:

  November 2017

• Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

  Id:

  TA496

  Published date:

  December 2017

• Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

  Id:

  TA169

  Published date:

  March 2009

• Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

  Id:

  TA410

  Published date:

  September 2016

• Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

  Id:

  TA396

  Published date:

  June 2016

• Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

  Id:

  TA208

  Published date:

  November 2010

• Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

  Id:

  TA405

  Published date:

  August 2016

• Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

  Id:

  TA269

  Published date:

  December 2012

• Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

  Id:

  TA272

  Published date:

  January 2013

Diagnostics guidance

Review new diagnostic technologies for adoption in the NHS.

• EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

  Id:

  DG9

  Published date:

  August 2013

• Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

  Id:

  DG8

  Published date:

  August 2013

Interventional procedures guidance

Assessments of whether procedures are safe enough and work well enough for wider use in the NHS. 

• Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer (IPG488)

  Id:

  IPG488

  Published date:

  May 2014

• Cryotherapy for the treatment of liver metastases (IPG369)

  Id:

  IPG369

  Published date:

  December 2010

• Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG331)

  Id:

  IPG331

  Published date:

  February 2010

• Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)

  Id:

  IPG446

  Published date:

  March 2013

• Irreversible electroporation for treating liver metastases (IPG445)

  Id:

  IPG445

  Published date:

  February 2013

• Microwave ablation for treating liver metastases (IPG553)

  Id:

  IPG553

  Published date:

  April 2016

• Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)

  Id:

  IPG179

  Published date:

  June 2006

Evidence summaries

Review the best available evidence for selected medicines.

• Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

  Id:

  ESNM13

  Published date:

  March 2013

• Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

  Id:

  ESUOM50

  Published date:

  January 2016

Medtech innovation briefings

Review the evidence and likely costs of medical devices and technologies.

• Caris Molecular Intelligence for guiding cancer treatment (MIB120)

  Id:

  MIB120

  Published date:

  September 2017

• OSNA for colon cancer staging (MIB77)

  Id:

  MIB77

  Published date:

  August 2016

• Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

  Id:

  MIB137

  Published date:

  January 2018

In development

• Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Apalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1534

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer [ID1522]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Breast cancer (brain metastases) - etirinotecan pegol [ID881]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Encorafenib with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID923]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  April 2019

• Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer ID1541

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2020

• Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• IMCgp100 for treating metastatic uveal melanoma (ID1441)

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]

  In consultation

  Yes

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Consultation ends:

  12 January 2019

• Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2020

• Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  August 2020

• Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (ID1140)

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab in combination for locally recurrent inoperable or metastatic triple negative breast cancer ID1546

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  May 2020

• Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

New guidance and advice

Guidance and advice added since June 2018

• Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Apalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1534

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

  New

  Yes

  Id:

  TA525

  Programme:

  Technology appraisal guidance

  Published date:

  June 2018

• Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer [ID1522]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Brain tumours (primary) and brain metastases in adults (NG99)

  New

  Yes

  Id:

  NG99

  Programme:

  NICE guideline

  Published date:

  July 2018

• Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Encorafenib with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID923]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  April 2019

  Status:

  In development

• Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer ID1541

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2020

  Status:

  In development

• IMCgp100 for treating metastatic uveal melanoma (ID1441)

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

  New

  Yes

  Id:

  TA539

  Programme:

  Technology appraisal guidance

  Published date:

  August 2018

• Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

  New

  Yes

  Id:

  TA530

  Programme:

  Technology appraisal guidance

  Published date:

  July 2018

• Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]

  In consultation

  Yes

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

  Consultation ends:

  12 January 2019

• Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2020

  Status:

  In development

• PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  August 2020

  Status:

  In development

• Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

  New

  Yes

  Id:

  TA531

  Programme:

  Technology appraisal guidance

  Published date:

  July 2018

• Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (ID1140)

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pembrolizumab in combination for locally recurrent inoperable or metastatic triple negative breast cancer ID1546

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  May 2020

  Status:

  In development

• Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

Updated guidance and advice

Guidance and advice updated since June 2018

• Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

  Updated

  Yes

  Id:

  TA492

  Programme:

  Technology appraisal guidance

  Published date:

  December 2017

  Last updated:

  July 2018

• Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

  Updated

  Yes

  Id:

  TA522

  Programme:

  Technology appraisal guidance

  Published date:

  June 2018

  Last updated:

  July 2018

Get involved